Abstract
BACKGROUND: This study evaluated awareness, prevalence, and utilization of dihydropyrimidine dehydrogenase (DPD) testing and pharmacogenomics among oncologists, residents, and clinical pharmacists working in Palestinian hospitals. AIM: This study aimed to assess the knowledge and opinions of HCPsspecializing in oncology in Palestine regarding screening for DPYD testing prior to prescribing FP. METHODS: A cross-sectional survey was distributed to 106 HCPs across various hospitals in Palestine. RESULTS: A notable deficiency in training and implementation of pharmacogenomics was observed, with over 70% of participants lacking formal training in the field. Although there is high awareness of DPD deficiency and its impact, fewer than 50% of participants screen for DPD deficiency prior to prescribing fluoropyrimidines (FP). Standardization and promotion of DPD testing are low, and guidelines for prescribing FP are lacking, leading to variations in clinical practice. CONCLUSION: These findings highlight the need for enhanced training, standardized protocols, and increased awareness to improve patient safety and outcomes in cancer treatment in Palestine.